“Phase 2 Study of Cemiplimab in Patients With Advanced Cutaneous Squamous Cell Carcinoma (CSCC): Final Analysis from EMPOWER-CSCC-1 Groups 1, 2, and 3”. 2023. SKIN The Journal of Cutaneous Medicine 7 (2): s176. https://doi.org/10.25251/skin.7.supp.176.